Intensity Therapeutics, Inc.
INTS
$4.04
$0.020.50%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.40M | 5.31M | 5.19M | 4.79M | 5.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.48M | 11.10M | 11.97M | 12.04M | 12.87M |
| Operating Income | -11.48M | -11.10M | -11.97M | -12.04M | -12.87M |
| Income Before Tax | -11.16M | -10.69M | -11.61M | -11.74M | -12.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.16 | -10.69 | -11.61 | -11.74 | -12.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.16M | -10.69M | -11.61M | -11.74M | -12.58M |
| EBIT | -11.48M | -11.10M | -11.97M | -12.04M | -12.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.93 | -7.18 | -11.74 | -15.95 | -20.76 |
| Normalized Basic EPS | -3.08 | -4.49 | -7.34 | -9.97 | -12.98 |
| EPS Diluted | -6.24 | -8.49 | -13.05 | -15.95 | -20.76 |
| Normalized Diluted EPS | -3.08 | -4.49 | -7.34 | -9.97 | -12.98 |
| Average Basic Shares Outstanding | 9.29M | 7.34M | 5.41M | 3.66M | 2.49M |
| Average Diluted Shares Outstanding | 9.29M | 7.34M | 5.41M | 3.66M | 2.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |